<a href="https://www.fiercebiotech.com/biotech/lilly-preps-ph-2-launch-after-verve-gene-editor-cuts-cholesterol-par-pcsk9-inhibitors" hreflang="en">Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors</a>
Eli Lilly is preparing for a phase 2 trial of its gene-editing treatment, VERVE-102, which has demonstrated a 62% reduction in cholesterol levels comparable to existing PCSK9 inhibitors, with effects lasting up to 18 months. The treatment aims to provide a durable solution for patients with genetically driven high cholesterol, potentially addressing the challenges of adherence to current cholesterol-lowering medications.
Eli Lilly's phase 2 trial preparation for the gene editor VERVE-102, which achieved a 62% LDL cholesterol reduction, highlights a significant advancement in gene editing for cardiovascular diseases. This progress in base editing offers a promising opportunity for healthtech investors and professionals engaged in precision medicine, as it could potentially revolutionize treatment options for patients with genetically driven high cholesterol, positioning it as a strong competitor to current PCSK9 inhibitors.